AI-generated summary
The authors randomized 75 high-dose methotrexate treatment episodes in 31 pediatric patients to intraoral or extraoral red light (660 nm) photobiomodulation to prevent oral mucositis. Oral mucositis occurred in 59.5% of intraoral episodes and 31.6% of extraoral episodes, with higher risk associated with intraoral treatment; extraoral treatment also needed less application time.
- Participants
- 31
- Who or what was studied
- Pediatric patients aged 1 to 18 years receiving high-dose methotrexate chemotherapy
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract reports an open-label design, pain and salivary outcomes were secondary or exploratory with no significant between-group differences, and the abstract does not state a specific limitation of the study.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Aims
To compare intraoral (IO) and extraoral (EO) photobiomodulation therapy (PBMT) for preventing oral mucositis (OM) in pediatric patients receiving high-dose methotrexate (HD-MTX).
Methods And Results
This prospective, open-label, randomized clinical trial included 75 HD-MTX treatment episodes from 31 pediatric patients aged 1-18 years. Each episode was randomized to IO-PBMT or EO-PBMT with red light at 660 nm. Preventive PBMT was initiated before HD-MTX infusion and administered daily until discharge. OM was assessed at baseline and on days 3, 5, and 10 using the World Health Organization scale. Pain, salivary pH, and salivary biochemical profiles were secondary or exploratory outcomes. Cumulative OM occurred in 22/37 IO-PBMT episodes (59.5%) and 12/38 EO-PBMT episodes (31.6%). After accounting for repeated episodes within patients, OM risk was higher with IO-PBMT (risk ratio, 1.84; 95% CI, 1.07-3.19; p = 0.029). Pain scores, salivary pH, and biochemical profiles did not differ significantly between groups. EO-PBMT required substantially less application time, and no adverse effects were reported.
Conclusion
EO-PBMT was associated with lower cumulative OM occurrence, shorter application time, and good tolerability, supporting its use as a promising, less burdensome preventive strategy in pediatric oncology.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Oral mucositis, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.